1. Social Implications of Hyperfunctional Facial Lines
2. 2.National Consumers League. American attitudes toward measures to treat visible signs of aging 2004. Available at http://www.nclnet.org/health/anti-aging/execsummary.htm. Accessed September 18, 2006.
3. 3.American Society of Plastic Surgeons. Restylane and other injectables at a glance 2005. Available at http://www.plasticsurgery.org/news_room/press_releases/Injectables-at-a-Glance.cfm. Accessed September 21, 2005.
4. 4.U. Bauer Poly-L-lactic acid (PLLA) in the correction of HIV-related facial lipoatrophy: duration of effect at 40 months post-treatment initiation. American Academy of Cosmetic Surgery 22nd Annual Scientific Meeting. January 26-29, 2006. 5. Sculptra (injectable poly-L-lactic acid). Prescribing Information. Dermik Laboratories. A business of Sanofi-Aventis US LLC, Bridgewater, NJ 08807. Available at http://products.sanofi-aventis.us/sculptra/sculptra.html. Accessed October 31, 2006. 6. Gogolewski S, Jovanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993: 27: 1135-1148. 7. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (Sculptra) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003: 17: 2471-2477. 8. Moyle GJ, Lysakova L, Brown S, et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004: 5: 82-87. 9. Woerle B, Hanke CW, Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 2004: 3: 385-389. 10. Radiesse. Radiesse currently has the following FDA clearances. Bioform, 2006. Available at http://www.radiesse.com/radiesse-usa.html. Accessed October 10, 2006. 11. Mechcatie E. FDA panel backs Radiesse approval, with conditions: physician training program recommended. Skin and Allergy News 2006. Available at http://www.skinandallergynews.com/article/PIIS0037633706715686/fulltext. Accessed October 15, 2006. 12. Tzikas TL. Evaluation of the Radiance FNtm soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004: 6: 234-239. 13. AIDSMEDS.com. Changes to your face (facial lipoatrophy) 2005. Available at http://www.aidsmeds.com/lessons/Lipoatrophy.htm. Accessed September 21, 2005. 14. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthet Plast Surg 2003: 27: 354-366. 15. Knapp TR, Kaplan EN, Daniels JR. Injectable collagen for soft tissue augmentation. Plast Reconstr Surg 1977: 60: 398-405. 16. Cofrancesco J Jr, Brown T, Martins CR. Management options for facial lipoatrophy. AIDS Read 2004: 14: 639-640, 645-650. Available at http://www.medscape.com/viewarticle/495994_print. Accessed September 20, 2005. 17. Roth JS. Restorative treatment approaches for HIV-associated lipoatrophy. The PRN Notebook 2005. Available at http://www.prn.org/prn_nb_cntnt/vol10/num3/roth_v10-n3_frm.htm. Accessed September 22, 2005.
5. 5.Sculptra (injectable poly-L-lactic acid). Prescribing Information. Dermik Laboratories. A business of Sanofi-Aventis US LLC, Bridgewater, NJ 08807. Available at http://products.sanofi-aventis.us/sculptra/sculptra.html. Accessed October 31, 2006.